VALN Key Statistics, Chart & Performance
The current stock price of VALN is 9.77 USD. In the past month the price increased by 16.87%. In the past year, price increased by 99.39%.
VALN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to VALN. When comparing the yearly performance of all stocks, VALN is one of the better performing stocks in the market, outperforming 92.86% of all stocks.
VALN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VALN. VALN has a bad profitability rating. Also its financial health evaluation is rather negative.
VALN Financial Highlights
Over the last trailing twelve months VALN reported a non-GAAP Earnings per Share(EPS) of -1.58. The EPS decreased by -1180% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.86% | ||
| ROE | -80.02% | ||
| Debt/Equity | 0.89 |
VALN Forecast & Estimates
11 analysts have analysed VALN and the average price target is 16.85 USD. This implies a price increase of 72.46% is expected in the next year compared to the current price of 9.77.
For the next year, analysts expect an EPS growth of -664.71% and a revenue growth -6.69% for VALN
VALN Ownership
About VALN
Company Profile
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Company Info
VALNEVA SE - ADR
6, Rue Alain Bombard
Saint-Herblain PAYS DE LA LOIRE FR
CEO: Thomas Lingelbach
Employees: 695
Phone: 33228073710
VALNEVA SE - ADR / VALN FAQ
What does VALN do?
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 695 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
What is the current price of VALN stock?
The current stock price of VALN is 9.77 USD. The price decreased by -5.1% in the last trading session.
Does VALN stock pay dividends?
VALN does not pay a dividend.
How is the ChartMill rating for VALNEVA SE - ADR?
VALN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is VALNEVA SE - ADR (VALN) expected to grow?
The Revenue of VALNEVA SE - ADR (VALN) is expected to decline by -6.69% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for VALNEVA SE - ADR?
VALNEVA SE - ADR (VALN) will report earnings on 2026-03-18, after the market close.